NanoString Technologies, Inc., which develops life-science research tools, including analytical systems used by cancer researchers to study the activity of genes in small tissue samples, has announced the pricing of its follow-on public offering of $55 million of common stock at $18.50 a share. It has also granted underwriters the option to purchase up to $8.25 million more of its common stock. The Seattle, Washington-based company plans to use the proceeds to further commercialize its Prosigna™ Breast Cancer Prognostic Gene Signature Assay by establishing a dedi- cated oncology sales force and expanding the test’s clinical utility. Details about the company’s previous funding initiatives appear in Issue 25 of this Bulletin. See NanoString News Release, January 23, 2014.